All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating tisagenlecleucel in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
Tisagenlecleucel is an anti‐CD19 chimeric antigen receptor T (CAR T) cell, currently approved for the treatment of pediatric and young adult patients (up to 25 years of age) with R/R acute lymphoblastic leukemia, and adult patients with R/R diffuse large B-cell lymphoma. In April, tisagenlecleucel received U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy designation for the treatment of patients with R/R FL, based on preliminary results from the ELARA trial.
The ELARA trial is a single-arm, multicenter, open-label trial investigating the efficacy and safety of tisagenlecleucel in adult patients with R/R FL. At the interim analysis, the study met the primary endpoint of complete response rate, with no new safety signals observed.
Severe side effects associated with tisagenlecleucel included cytokine release syndrome (CRS) and neurological toxicities. Due to the risk of CRS and neurologic toxicities, tisagenlecleucel is only available through a restricted program under a risk evaluation and mitigation strategy.
Results from the ELARA trial will be included in US and EU regulatory submissions.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox